<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="66981">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01703039</url>
  </required_header>
  <id_info>
    <org_study_id>2012P001841</org_study_id>
    <nct_id>NCT01703039</nct_id>
  </id_info>
  <brief_title>Riluzole Augmentation Pilot in Depression (RAPID) Trial</brief_title>
  <acronym>RAPID</acronym>
  <official_title>Riluzole Augmentation Pilot in Depression (RAPID) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are doing a research study to find out if riluzole, when taken along with
      a standard antidepressant (sertraline) can help people with major depression.

      This research study will compare riluzole + sertraline to placebo + sertraline. The
      investigators hypothesize that adding riluzole will lead to a better antidepressant
      response, in less time, then sertraline alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent attention has focused on the glutamatergic system as a new, distinct target for
      depression treatment. Riluzole (Rilutek, Sanofi), an oral modulator of glutamate activity
      with neuroprotective and anticonvulsant properties, is currently approved by the United
      States Food and Drug Administration for treatment of amyotrophic lateral sclerosis (ALS).
      Preliminary studies using riluzole to treat depression in humans are promising, though
      larger, double-blinded controlled trials are needed.

      Overall study population:

      Adult outpatients with a current, untreated major depressive episode.

      Disallowed therapies include: other psychotropic medications, including antipsychotics, mood
      stabilizers, benzodiazepines, barbiturates, other sedative-hypnotics, chronic opiates, or
      additional antidepressants, psychotherapy, electroconvulsive therapy, vagal nerve
      stimulations therapy, transcranial magnetic stimulation therapy, or phototherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean change in Hamilton Depression Rating Scale (HDRS) score from baseline to endpoint at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients experiencing an antidepressant response (&gt;50% reduction in HDRS) at endpoint of 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients experiencing remission from depression (HDRS&lt;7) at endpoint of 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in Hamilton Anxiety Rating Scale (HARS) score from baseline to endpoint at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in Clinical Global Impression (CGI) scale from baseline to endpoint at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>sertraline + riluzole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sertraline 100 mg po daily and riluzole 50 mg po bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sertraline + placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sertraline 100 mg po daily and placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riluzole</intervention_name>
    <arm_group_label>sertraline + riluzole</arm_group_label>
    <other_name>Rilutek</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <arm_group_label>sertraline + riluzole</arm_group_label>
    <arm_group_label>sertraline + placebo</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>sertraline + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (ages 18-75) who meet DSM-IV criteria for a major depressive episode,

          -  Hamilton Depression Rating Scale (HDRS) &gt;22, and

          -  No antidepressant treatment for at least three weeks

        Exclusion Criteria:

          -  Active drug or alcohol disorder in the past 3 months

          -  History of psychosis, history of mania or hypomania

          -  Epilepsy or history of seizures

          -  Hypothyroidism

          -  Congenital QTc prolongation

          -  Liver disease

          -  Lung disease

          -  Acute suicide or homicide risk

          -  Pregnant women, breastfeeding women, women of childbearing age not using
             contraception

          -  Unstable medical illness

          -  Elevated thyroid-stimulating hormone (TSH&gt;5.0mlU/L), or

          -  Abnormal liver function tests (ALT&gt;50 U/L or AST&gt;50 U/L)

        Disallowed therapies include: other psychotropic medications, including antipsychotics,
        mood stabilizers, benzodiazepines, barbiturates, other sedative-hypnotics, chronic
        opiates, or additional antidepressants, psychotherapy, electroconvulsive therapy, vagal
        nerve stimulations therapy, transcranial magnetic stimulation therapy, or phototherapy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J Wolfe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David J Wolfe, MD</last_name>
    <phone>617-525-8806</phone>
    <email>DWOLFE@PARTNERS.ORG</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sutanuka Lahiri, MS</last_name>
      <email>SLAHIRI@PARTNERS.ORG</email>
    </contact>
    <contact_backup>
      <last_name>David Wolfe, MD</last_name>
      <email>DWOLFE@PARTNERS.ORG</email>
    </contact_backup>
    <investigator>
      <last_name>David J Wolfe, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 29, 2013</lastchanged_date>
  <firstreceived_date>October 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>David John Wolfe</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <keyword>Major Depression</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Depression</keyword>
  <keyword>Riluzole</keyword>
  <keyword>Glutamate</keyword>
  <keyword>Sertraline</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Riluzole</mesh_term>
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
